Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats | Wang et al. Journal of Orthopaedic Surgery and Research 2011 6 34 http content 6 1 34 JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH RESEARCH ARTICLE Open Access Alendronate ALN combined with Osteoprotegerin OPG significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats Yan Wang1 Peng Huang1 Pei-Fu Tang1 Kai-Ming Chan2 3 and Gang Li2 3 4 Abstract Background Alendronate ALN is the most common form of bisphosphonates used for the treatment of osteoporosis. Osteoprotegerin OPG has also been shown to reduce osteoporotic changes in both humans and experimental animals after systemic administration. The aim of this current study was to test if the anti-resorption effects of ALN may be enhanced when used in combination with OPG. Objectives To investigate the effects of ALN OPG or combined on bone mass and bone mechanical properties in ovariectomized OVX rats. Methods OVX rats were treated with ALN OPG-Fc or OPG-Fc and ALN. Biochemical markers trabecular bone mass biomechanics histomorphometry and RANKL expression in the bone tissues were examined following the treatments. Results The treatment of ALN OPG-Fc and ALN OPG-Fc all prevented bone loss in the OVX-rats there was no statistical difference among the three treatment groups in terms of vertebrae BMD mineralizing surfaces mineral apposition rate BFR BS. The ALN OPG-Fc treatment group had significantly increased the mechanical strength of lumber vertebral bodies and femoral shafts when compared to the ALN and OPG-Fc treatment groups. The RANKL protein expression in the vertebral bones was significantly decreased in the ALN and ALN OPG-Fc treatment groups suggesting the combined use of OPG-Fc and ALN might have amplified inhibition of bone resorption through inhibiting RANKL-dependent osteoclastogenesis. Conclusion The combined use of OPG-Fc and ALN may be a new treatment strategy for reversing bone loss and restoring bone quality in .
